RPB5‐Mediating Protein Promotes Cholangiocarcinoma Tumorigenesis and Drug Resistance by Competing With NRF2 for KEAP1 Binding

Zheng‐Hua Wan, Tian‐Yi Jiang, Yuan‐Yuan Shi, Yu‐Fei Pan, Yun‐Kai Lin, Yun‐Han Ma, Chun Yang, Xiao‐Fan Feng, Li‐Feng Huang, Xiao‐Ni Kong, Zhi‐Wen Ding, Ye‐Xiong Tan, Li‐Wei Dong, Hong‐Yang Wang – 21 September 2019

The Tumor Suppressor Interferon Regulatory Factor 2 Binding Protein 2 Regulates Hippo Pathway in Liver Cancer by a Feedback Loop in Mice

Xue Feng, Tiantian Lu, Jinhui Li, Ruizeng Yang, Liqiao Hu, Yi Ye, Feifei Mao, Lingli He, Jinjin Xu, Zuoyun Wang, Yingbin Liu, Yonglong Zhang, Hongbin Ji, Yun Zhao, Shuqun Cheng, Wei Tian, Lei Zhang – 20 September 2019

Intraoperative Events in Liver Transplantation Using Donation After Circulatory Death Donors

Ryan M. Chadha, Kristopher P. Croome, Stephen Aniskevich, Sher‐Lu Pai, Justin Nguyen, Justin Burns, Dana Perry, C. Burcin Taner – 20 September 2019 – Liver grafts from donation after circulatory death (DCD) are a source of organs to decrease wait‐list mortality. While there have been lower rates of graft loss, there are concerns of an increased incidence of intraoperative events in recipients of DCD grafts. We aim to look at the incidence of intraoperative events between recipients of livers from DCD and donation after brain death (DBD) donors.

Temporal Changes and Regional Variation in Acceptance of Hepatitis C Virus–Viremic Livers

Rafal D. Mazur, David S. Goldberg – 20 September 2019 – The high efficacy of current hepatitis C virus (HCV) therapy and increased numbers of HCV‐infected deceased donors have changed the paradigm of HCV in liver transplantation (LT). Modeling studies have been performed to evaluate the optimal timing of HCV treatment (before versus after LT) in HCV‐infected patients and to assess the cost‐effectiveness of transplanting HCV‐infected livers into HCV− patients.

Subscribe to